3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.

Citation (Vancouver)

Assefa Y, Assefa Y, Woldeyohannes S, Hamada Y, Getahun H. 3-month daily rifampicin and isoniazid compared to 6-or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review. European Respiratory Journal. 2018 Jul 1;52(1).

Abstract

One-third to one-quarter of the world’s population is estimated to have latent tuberculosis infection (LTBI) . These infected persons are at risk for developing active disease with a lifetime risk of reactivation estimated to be 5–10% . Prevention of reactivation of LTBI in population groups with higher risk of progression to active disease than the general population, is critical to end the global TB epidemic .